Compare Stocks: AKBA, JANX, ANL, and ALMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 +4.4%	$1.04	$0.81 ▼ $3.20	$260.06M	0.19	8.67 million shs	5.09 million shs
ALMS Alumis	$8.11 +2.7%	$20.78	$3.76 ▼ $31.35	$1.02B	-0.81	4.74 million shs	2.52 million shs
ANL Adlai Nortye	$16.60 +6.6%	$13.78	$0.88 ▼ $17.25	$1.00B	1.04	164,054 shs	105,179 shs
JANX Janux Therapeutics	$17.47 +2.7%	$17.04	$12.12 ▼ $35.34	$1.04B	2.53	941,423 shs	826,060 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.49%	-2.53%	+3.52%	-14.68%	-66.72%
ALMS Alumis	+1.67%	-14.32%	-67.31%	-67.77%	+89.45%
ANL Adlai Nortye	-1.08%	-2.26%	+13.65%	+46.89%	+794.31%
JANX Janux Therapeutics	+2.53%	-1.73%	-2.19%	+14.08%	-27.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 +4.4%	$1.04	$0.81 ▼ $3.20	$260.06M	0.19	8.67 million shs	5.09 million shs
ALMS Alumis	$8.11 +2.7%	$20.78	$3.76 ▼ $31.35	$1.02B	-0.81	4.74 million shs	2.52 million shs
ANL Adlai Nortye	$16.60 +6.6%	$13.78	$0.88 ▼ $17.25	$1.00B	1.04	164,054 shs	105,179 shs
JANX Janux Therapeutics	$17.47 +2.7%	$17.04	$12.12 ▼ $35.34	$1.04B	2.53	941,423 shs	826,060 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.49%	-2.53%	+3.52%	-14.68%	-66.72%
ALMS Alumis	+1.67%	-14.32%	-67.31%	-67.77%	+89.45%
ANL Adlai Nortye	-1.08%	-2.26%	+13.65%	+46.89%	+794.31%
JANX Janux Therapeutics	+2.53%	-1.73%	-2.19%	+14.08%	-27.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.43	Hold	$3.90	297.96% Upside
ALMS Alumis	2.85	Moderate Buy	$33.27	310.27% Upside
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	77.71% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	108.71% Upside

Current Analyst Ratings Breakdown

Latest AKBA, JANX, ANL, and ALMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.15	N/A	N/A	$0.12 per share	8.17
ALMS Alumis	$24.05M	43.65	N/A	N/A	$2.88 per share	2.82
ANL Adlai Nortye	$5M	213.81	N/A	N/A	($0.21) per share	-79.05
JANX Janux Therapeutics	$10M	106.81	N/A	N/A	$15.91 per share	1.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)

Latest AKBA, JANX, ANL, and ALMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
ALMS Alumis	N/A	6.74	6.74
ANL Adlai Nortye	0.04	9.55	0.65
JANX Janux Therapeutics	N/A	16.35	16.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ALMS Alumis	N/A
ANL Adlai Nortye	35.21%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
ALMS Alumis	33.70%
ANL Adlai Nortye	N/A
JANX Janux Therapeutics	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable

AKBA, JANX, ANL, and ALMS Headlines

Recent News About These Companies

Financial Contrast: Abeona Therapeutics (NASDAQ:ABEO) and Janux Therapeutics (NASDAQ:JANX)

September 21 at 5:28 AM | americanbankingnews.com

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed

September 18, 2026 | seekingalpha.com

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 17, 2026 | seekingalpha.com

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

September 15, 2026 | zacks.com

Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate

September 14, 2026 | finance.yahoo.com

Janux Therapeutics Doses First Patient In Phase 1 Study Of JANX013

September 14, 2026 | rttnews.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

September 14, 2026 | finance.yahoo.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

September 14, 2026 | businesswire.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts

September 14, 2026 | americanbankingnews.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 14, 2026 | marketbeat.com

Squarepoint Ops LLC Has $8.18 Million Holdings in Janux Therapeutics, Inc. $JANX

September 11, 2026 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 7.2% - Here's What Happened

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.08 Million in Janux Therapeutics, Inc. $JANX

September 8, 2026 | marketbeat.com

Wellington Management Group LLP Sells 90,290 Shares of Janux Therapeutics, Inc. $JANX

September 6, 2026 | marketbeat.com

Jupiter Topco LLC Purchases New Stake in Janux Therapeutics, Inc. $JANX

September 3, 2026 | marketbeat.com

Man Group plc Has $3.82 Million Position in Janux Therapeutics, Inc. $JANX

August 31, 2026 | marketbeat.com

BlackRock Inc. Purchases New Shares in Janux Therapeutics, Inc. $JANX

August 30, 2026 | marketbeat.com

Nantahala Capital Management LLC Invests $12.44 Million in Janux Therapeutics, Inc. $JANX

August 29, 2026 | marketbeat.com

Janux Therapeutics, Inc. $JANX Shares Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Raised to Strong-Buy at TD Cowen

August 25, 2026 | marketbeat.com

Algert Global LLC Buys 667,492 Shares of Janux Therapeutics, Inc. $JANX

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AKBA, JANX, ANL, and ALMS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.98 +0.04 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.20%)

As of 07:59 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alumis NASDAQ:ALMS

$8.11 +0.21 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$8.10 -0.01 (-0.15%)

As of 07:50 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Adlai Nortye NASDAQ:ANL

$16.60 +1.03 (+6.62%)

Closing price 04:00 PM Eastern

Extended Trading

$16.60 -0.01 (-0.03%)

As of 07:32 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Janux Therapeutics NASDAQ:JANX

$17.47 +0.46 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$17.46 0.00 (-0.03%)

As of 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, JANX, ANL, and ALMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, JANX, ANL, and ALMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, JANX, ANL, and ALMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, JANX, ANL, and ALMS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Alumis NASDAQ:ALMS

Adlai Nortye NASDAQ:ANL

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, JANX, ANL, and ALMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, JANX, ANL, and ALMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, JANX, ANL, and ALMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, JANX, ANL, and ALMS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Alumis NASDAQ:ALMS

Adlai Nortye NASDAQ:ANL

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools